RS58390B1 - Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora - Google Patents

Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora

Info

Publication number
RS58390B1
RS58390B1 RS20190264A RSP20190264A RS58390B1 RS 58390 B1 RS58390 B1 RS 58390B1 RS 20190264 A RS20190264 A RS 20190264A RS P20190264 A RSP20190264 A RS P20190264A RS 58390 B1 RS58390 B1 RS 58390B1
Authority
RS
Serbia
Prior art keywords
triazolo
receptor antagonists
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
RS20190264A
Other languages
English (en)
Inventor
Stephan Roever
Mark Rogers-Evans
Matthias Nettekoven
Sébastien Schmitt
Uwe Grether
Atsushi Kimbara
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS58390B1 publication Critical patent/RS58390B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
RS20190264A 2013-09-06 2014-09-03 Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora RS58390B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183385 2013-09-06
PCT/EP2014/068640 WO2015032769A1 (en) 2013-09-06 2014-09-03 Novel triazolo[4,5-d]pyrimidine derivatives
EP14761320.2A EP3041843B1 (en) 2013-09-06 2014-09-03 Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists

Publications (1)

Publication Number Publication Date
RS58390B1 true RS58390B1 (sr) 2019-04-30

Family

ID=49111076

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190264A RS58390B1 (sr) 2013-09-06 2014-09-03 Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
RS20211007A RS62234B1 (sr) 2013-09-06 2014-09-03 Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20211007A RS62234B1 (sr) 2013-09-06 2014-09-03 Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora

Country Status (32)

Country Link
US (1) US9593123B2 (sr)
EP (3) EP3943497A1 (sr)
JP (1) JP6441356B2 (sr)
KR (3) KR102349567B1 (sr)
CN (1) CN105555788B (sr)
AR (1) AR097553A1 (sr)
AU (1) AU2014317229B2 (sr)
CA (1) CA2915766C (sr)
CL (1) CL2016000495A1 (sr)
CR (1) CR20160076A (sr)
DK (2) DK3483163T3 (sr)
EA (1) EA028335B1 (sr)
ES (2) ES2883923T3 (sr)
HK (1) HK1219277A1 (sr)
HR (2) HRP20190361T1 (sr)
HU (2) HUE041760T2 (sr)
IL (1) IL243092B (sr)
LT (2) LT3483163T (sr)
MA (1) MA38826B1 (sr)
MX (2) MX367084B (sr)
MY (1) MY191628A (sr)
PE (2) PE20160691A1 (sr)
PH (1) PH12016500250A1 (sr)
PL (2) PL3041843T3 (sr)
PT (2) PT3483163T (sr)
RS (2) RS58390B1 (sr)
SG (1) SG11201601714UA (sr)
SI (2) SI3041843T1 (sr)
TR (1) TR201900662T4 (sr)
TW (1) TWI705966B (sr)
UA (1) UA116395C2 (sr)
WO (1) WO2015032769A1 (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162630A1 (en) * 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
WO2016071375A1 (en) 2014-11-07 2016-05-12 F. Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017076266A1 (zh) * 2015-11-06 2017-05-11 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]***并[4,5-d]嘧啶衍生物
SG10202113286RA (en) * 2016-06-23 2021-12-30 Hoffmann La Roche [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
JP7090037B2 (ja) * 2016-06-23 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
CN106478639B (zh) * 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432247B (zh) * 2016-09-27 2018-06-29 郑州大学 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用
CN106432248B (zh) * 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN106928296A (zh) * 2017-02-06 2017-07-07 上海华升生物科技有限公司 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法
CN106928235A (zh) * 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN107033148B (zh) * 2017-05-03 2018-10-26 郑州大学 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用
CN109516990B (zh) * 2017-09-19 2021-06-01 天津药物研究院有限公司 嘧啶并三氮唑类化合物、其制备方法和用途
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN115246832A (zh) * 2022-06-15 2022-10-28 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2008503464A (ja) * 2004-06-17 2008-02-07 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 習慣性行動の１つ以上の構成要素の改善のためのアデノシンａ２ａレセプターの拮抗
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2008141249A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2013060837A1 (en) 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
CN104395290A (zh) 2012-07-04 2015-03-04 霍夫曼-拉罗奇有限公司 作为***素受体2激动剂的新金刚烷基衍生物
US9303012B2 (en) 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
CN104837831B (zh) 2012-12-07 2017-10-31 霍夫曼-拉罗奇有限公司 新的吡啶衍生物
PE20151060A1 (es) 2012-12-07 2015-07-25 Hoffmann La Roche Nuevos derivados de pirazina como agonistas del receptor cb2
MX2015007156A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
WO2014135507A1 (en) 2013-03-07 2014-09-12 F. Hoffmann-La Roche Ag Novel pyrazol derivatives
KR20210145303A (ko) 2013-05-02 2021-12-01 에프. 호프만-라 로슈 아게 Cb2 수용체 작용제로서의 퓨린 유도체
CA2907691A1 (en) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
EP3008055B1 (en) 2013-06-11 2017-07-19 F. Hoffmann-La Roche AG Tetrazolone derivatives

Also Published As

Publication number Publication date
LT3483163T (lt) 2021-09-10
MA38826B1 (fr) 2016-12-30
CN105555788B (zh) 2018-11-23
AU2014317229A1 (en) 2016-01-07
TW201542551A (zh) 2015-11-16
DK3041843T3 (en) 2019-03-25
NZ756513A (en) 2021-05-28
TWI705966B (zh) 2020-10-01
PE20191528A1 (es) 2019-10-23
RS62234B1 (sr) 2021-09-30
PL3483163T3 (pl) 2021-11-22
SG11201601714UA (en) 2016-04-28
MX2019009100A (es) 2019-09-16
MY191628A (en) 2022-07-04
KR102349567B1 (ko) 2022-01-11
SI3041843T1 (sl) 2019-04-30
IL243092B (en) 2019-06-30
US20160168158A1 (en) 2016-06-16
EA201690478A1 (ru) 2016-06-30
LT3041843T (lt) 2019-03-12
KR20220140651A (ko) 2022-10-18
ES2714094T3 (es) 2019-05-27
CR20160076A (es) 2016-04-01
KR20160050061A (ko) 2016-05-10
KR20210074404A (ko) 2021-06-21
HK1219277A1 (zh) 2017-03-31
HUE055201T2 (hu) 2021-11-29
CA2915766C (en) 2023-09-26
NZ715085A (en) 2021-05-28
ES2883923T3 (es) 2021-12-09
DK3483163T3 (da) 2021-08-30
AR097553A1 (es) 2016-03-23
EP3041843A1 (en) 2016-07-13
PT3041843T (pt) 2019-02-26
CN105555788A (zh) 2016-05-04
JP6441356B2 (ja) 2018-12-19
EP3943497A1 (en) 2022-01-26
HUE041760T2 (hu) 2019-05-28
PH12016500250B1 (en) 2016-05-16
TR201900662T4 (tr) 2019-02-21
MX367084B (es) 2019-08-05
PL3041843T3 (pl) 2019-06-28
PH12016500250A1 (en) 2016-05-16
UA116395C2 (uk) 2018-03-12
MA38826A1 (fr) 2016-05-31
HRP20211322T1 (hr) 2021-11-26
EP3483163A2 (en) 2019-05-15
US9593123B2 (en) 2017-03-14
EP3483163A3 (en) 2019-07-24
EP3483163B1 (en) 2021-06-23
EP3041843B1 (en) 2019-01-02
CA2915766A1 (en) 2015-03-12
SI3483163T1 (sl) 2021-11-30
IL243092A0 (en) 2016-02-01
AU2014317229B2 (en) 2018-11-08
KR102454344B1 (ko) 2022-10-14
WO2015032769A1 (en) 2015-03-12
HRP20190361T1 (hr) 2019-04-05
CL2016000495A1 (es) 2016-10-07
PE20160691A1 (es) 2016-07-28
PT3483163T (pt) 2021-08-24
JP2016532707A (ja) 2016-10-20
MX2016002117A (es) 2016-07-05
EA028335B1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
HK1245764A1 (zh) 3-取代的5-氨基-6h-噻唑並[4，5-d]嘧啶-2，7-二酮化合物
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
ZA201402905B (en) [1,2,3]triazolo [4,5-d]pyrimidine derivatives as agonist of the cannabinoid receptor 2
IL242162B (en) Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists
IL232304A0 (en) [1,2,3]-Triazolo[4,5-d]pyrimidine derivatives are agonistic for cannabinoid receptor 2 agonists
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
IL250983A0 (en) Triazolo[4, 5-d]pyrimidines as cannabinoid receptor 2 agonists
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่